| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Executive VP and CLO | Executive VP and CLO
1 company
Boulding Mark Elliott serves as an Executive VP and CLO at PTCT. Across recent SEC filings that breaks down to 0 buys and 166 sells. Those positions are worth an estimated $6.8M at current prices.
Historically, Boulding Mark Elliott's trades have earned a middling insider score of 56/100 across 50 rated trades. Over a 12-month horizon, 33.3% of those trades were profitable, with an average 12-month return of -12.1%.
The biggest single holding is PTCT (~$6.8M) as Executive VP and CLO. The recent filings there lean toward selling, a net 671,251 shares.
| Date | Ticker | Role | Type | Shares | Price | Value | Chg% | 3M | 12M | SEC |
|---|---|---|---|---|---|---|---|---|---|---|
| Oct 9, 2026 | PTCT Ptc Therapeutics, Inc. | Executive VP and CLO | Sale+OE10b5-1 | 192 | $64.26 | $12,337.92 | -0.2% | - | - | |
| Oct 6, 2026 | PTCT Ptc Therapeutics, Inc. | Executive VP and CLO | Sale+OE10b5-1 | 2,073 | $64.06 | $132,790.74 | -1.9% | - | - | |
| Aug 17, 2026 | PTCT Ptc Therapeutics, Inc. | Executive VP and CLO | Sale+OE10b5-1 | 2,813 | $72.57 | $204,127.26 | -2.6% | - | - | |
| Jul 6, 2026 | PTCT Ptc Therapeutics, Inc. | Executive VP and CLO | Sale+OE10b5-1 | 5,079 | $85.08 | $432,117.53 | -4.6% | -25.5% | - | |
| Jun 17, 2026 | PTCT Ptc Therapeutics, Inc. | Executive VP and CLO | Sale+OE10b5-1 | 10,462 | $78.65 | $822,867.75 | -9.0% | -16.4% | - | |
| May 15, 2026 | PTCT Ptc Therapeutics, Inc. | Executive VP and CLO | Sale+OE10b5-1 | 2,812 | $72.18 | $202,958.00 | -2.6% | +0.7% | - | |
| May 8, 2026 | PTCT Ptc Therapeutics, Inc. | Executive VP and CLO | Sale+OE10b5-1 | 3,540 | $78.97 | $279,570.20 | -3.3% | -3.9% | - | |
| Apr 6, 2026 | PTCT Ptc Therapeutics, Inc. | Executive VP and CLO | Sale+OE10b5-1 | 2,265 | $69.45 | $157,293.27 | -2.1% | +24.0% | - | |
| Feb 19, 2026 | PTCT Ptc Therapeutics, Inc. | Executive VP and CLO | Sell10b5-1 | 3,019 | $69.48 | $209,762.58 | -2.8% | +1.6% | - | |
| Feb 18, 2026 | PTCT Ptc Therapeutics, Inc. | Executive VP and CLO | Sale+OE10b5-1 | 5,894 | $69.33 | $408,612.61 | -5.2% | +2.0% | - |